Sunday, December 12, 2010

San Antonio Breast Cancer Symposium 2010 Information

The San Antonio Breast Cancer Symposium attracts academic and private physicians and researchers, as well as other health care professionals focused on curing breast cancer, to discuss and learn about new and late-breaking research including experimental biology, etiology, prevention, diagnosis, and therapy of breast cancer and pre-malignant breast disease, as well as new findings from clinical trials. With the addition of the AACR as a symposium collaborator, this year’s program will attract more thought-leaders and high-quality proffered papers in basic and translational breast cancer research as well as increase the participation of young investigators by providing superior education and training opportunities for the next generation of breast cancer researchers.
You can view information about the symposium:
Abstracts from presentations are available on the website above.
The publication Cure Today has a daily email which reviews highlights of the presentations at the symposium each day. There are also video interviews with some of the presenters. You can view these daily hightlights at:
Following are two briefs that appear in the Cure Today highlights:
Highlights from the 2009 Symposium: An Update
Physicians, researchers and advocates from all around the world came away from the 2009 SABCS with answers to a number of important questions: Is beginning on an aromatase inhibitor better than switching from tamoxifen? Is Herceptin more effective with or following chemotherapy in HER2-positive breast cancer? Does Avastin slow progression of metastatic breast cancer and by how much? And how well does Xgeva work against bone pain and fracture when compared with Zometa? Get an update on last year's breaking news.
Preventing Cancer in BRCA Mutation Carriers
Every woman with a mutated BRCA1 or BRCA2 gene should have their ovaries removed to lower their risk of ovarian cancer, said speaker Susan Domchek, MD, during an educational session Wednesday at the SABCS. Calling the preventive surgery "mandatory" in BRCA1 and BRCA2 mutation carriers, Domchek said there's no evidence that current ovarian cancer screening is effective.
Click on the abstract name above to be taken to the full article referenced.
To view products that can help with side effects caused by breast cancer treatment, please visit: